Andrea Kakouri

Dr. Andrea Kakouri

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2018 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Open access
AKAndrea Kakouri
Andrea Kakouri
CCChristiana Christodoulou
Christiana Christodoulou
MZMargarita Zachariou
Margarita Zachariou
AOAnastasis Oulas
Anastasis Oulas
GSGeorge Spyrou
George Spyrou
GSGeorge Spyrou
George Spyrou
The advancement of scientific and medical research over the past years has generated a wealth of experimental data from multiple technologies, including genomics, transcriptomics, proteomics and other forms of -omics data, which are available for a number of diseases. The integration of such multisource data is a key component towards the success of precision medicine. In this work we are investigating a multisource data integration method developed by our group, regarding its ability to drive to clusters of connected pathways under two different approaches: (a) a disease-centric approach, where we want to integrate data around a disease, and (b) a gene-centric approach, where we want to integrate data around a gene. We have used as a paradigm for the first approach Huntington's disease (HD), a disease with a plethora of available data, whereas for the second approach the GBA2, a gene that is related to Spastic Ataxia (SA), a phenotype with sparse availability of data. Our work shows that valuable information at the level of disease-related pathway clusters can be obtained for both HD and SA. New pathways that classical pathway analysis methods were unable to reveal, are emerging as necessary “connectors” to build connected pathway stories formed as pathway clusters.

11 March 2022 in Neuromuscular Disorders
Verified
Journal Article
Open access
AKAndrie Koutsoulidou
Andrie Koutsoulidou
DKDemetris Koutalianos
Demetris Koutalianos
KGKristia Georgiou
Kristia Georgiou
AKAndrea Kakouri
Andrea Kakouri
AOAnastasis Oulas
Anastasis Oulas
Leonidas A. PhylactouLeonidas A. Phylactou
Leonidas A. Phylactou
Muscular dystrophies are a group of disorders that cause progressive muscle weakness. There is an increasing interest for the development of biomarkers for these disorders and specifically for Duchene Muscular Dystrophy. Limited research however, has been performed on the biomarkers' development for the most rare muscular dystrophies, like the Facioscapulohumeral Muscular Dystrophy, Limb-Girdle Muscular Dystrophy and Myotonic Dystrophy type 2. Here, we aimed to identify novel serum-based miRNA biomarkers for these rare muscular dystrophies, through high-throughput next-generation RNA sequencing. We identified many miRNAs that associate with muscular dystrophy patients compared to controls. Based on a series of selection criteria, the two best candidate miRNAs for each of these disorders were chosen and validated in a larger number of patients. Our results showed that miR-223-3p and miR-206 are promising serum-based biomarkers for Facioscapulohumeral Muscular Dystrophy type 1, miR-143-3p and miR-486-3p for Limb-Girdle Muscular Dystrophy type 2A whereas miR-363-3p and miR-25-3p associate with Myotonic Dystrophy type 2. Some of the identified miRNAs were significantly elevated in the serum of the patients compared to controls, whereas some others were lower. In conclusion, we provide new evidence that certain circulating miRNAs may be used as biomarkers for three types of rare muscular dystrophies.

7 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EKEvangelos Karatzas
Evangelos Karatzas
AKAndrea Kakouri
Andrea Kakouri
GKGeorge Kolios
George Kolios
ADAlex Delis
Alex Delis
GSGeorge Spyrou
George Spyrou
Fibrotic diseases cover a spectrum of systemic and organ-specific maladies that affect a large portion of the population, currently without cure. The shared characteristic these diseases feature is their uncontrollable fibrogenesis deemed responsible for the accumulated damage in the susceptible tissues.Idiopathic Pulmonary Fibrosis, an interstitial lung disease, is one of the most common and studied fibrotic diseases and still remains an active research target. In this study we highlight unique and common (i) genes, (ii) biological pathways and (iii) candidate repurposed drugs among 9 fibrotic diseases. We identify 7 biological pathways involved in all 9 fibrotic diseases as well as pathways unique to some of these diseases. Based on our Drug Repurposing results, we suggest captopril and ibuprofen that both appear to slow the progression of fibrotic diseases according to existing bibliography. We also recommend nafcillin and memantine, which haven’t been studied against fibrosis yet, for further wet-lab experimentation. We also observe a group of cardiomyopathy-related pathways that are exclusively highlighted forOral Submucous Fibrosis. We suggest digoxin to be tested againstOral Submucous Fibrosis, since we observe cardiomyopathy-related pathways implicated inOral Submucous Fibrosisand there is bibliographic evidence that digoxin may potentially clear myocardial fibrosis. Finally, we establish thatIdiopathic Pulmonary Fibrosisshares several involved genes, biological pathways and candidate inhibiting-drugs withDupuytren’s Disease,IgG4-related Disease,Systemic SclerosisandCystic Fibrosis. We propose that treatments for these fibrotic diseases should be jointly pursued.

15 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMIoannis Mamais
Ioannis Mamais
AMApostolos Malatras
Apostolos Malatras
GPGregory Papagregoriou
Gregory Papagregoriou
NGNatasa Giallourou
Natasa Giallourou
AKAndrea Kakouri
Andrea Kakouri
Constantinos DeltasConstantinos Deltas
Constantinos Deltas
Long-term persistence and the heterogeneity of humoral response to SARS-CoV-2 have not yet been thoroughly investigated. The aim of this work is to study the production of circulating immunoglobulin class G (IgG) antibodies against SARS-CoV-2 in individuals with past infection in Cyprus. Individuals of the general population, with or without previous SARS-CoV-2 infection, were invited to visit the Biobank at the Center of Excellence in Biobanking and Biomedical Research of the University of Cyprus. Serum IgG antibodies were measured using the SARS-CoV-2 IgG and the SARS-CoV-2 IgG II Quant assays of Abbott Laboratories. Antibody responses to SARS-CoV-2 were also evaluated against participants’ demographic and clinical data. All statistical analyses were conducted in Stata 16. The median levels of receptor binding domain (RBD)-specific IgG in 969 unvaccinated individuals, who were reportedly infected between November 2020 and September 2021, were 432.1 arbitrary units (AI)/mL (interquartile range—IQR: 182.4–1147.3). Higher antibody levels were observed in older participants, males, and those who reportedly developed symptoms or were hospitalized. The RBD-specific IgG levels peaked at three months post symptom onset and subsequently decreased up to month six, with a slower decay thereafter. IgG response to the RBD of SARS-CoV-2 is bi-phasic with considerable titer variability. Levels of IgG are significantly associated with several parameters, including age, gender, and severity of symptoms.

Verified
Journal Article
Open access
PDF file
AKAndrea Kakouri
Andrea Kakouri
CVChristina Votsi
Christina Votsi
MTMarios Tomazou
Marios Tomazou
GSGeorge Spyrou
George Spyrou
EKEvangelos Karatzas
Evangelos Karatzas
GSGeorge Spyrou
George Spyrou
Spastic ataxia (SA) is a group of rare neurodegenerative diseases, characterized by mixed features of generalized ataxia and spasticity. The pathogenetic mechanisms that drive the development of the majority of these diseases remain unclear, although a number of studies have highlighted the involvement of mitochondrial and lipid metabolism, as well as calcium signaling. Our group has previously published the GBA2 c.1780G > C (p.Asp594His) missense variant as the cause of spastic ataxia in a Cypriot consanguineous family, and more recently the biochemical characterization of this variant in patients’ lymphoblastoid cell lines. GBA2 is a crucial enzyme of sphingolipid metabolism. However, it is unknown if GBA2 has additional functions and therefore additional pathways may be involved in the disease development. The current study introduces bioinformatics approaches to better understand the pathogenetic mechanisms of the disease. We analyzed publicly available human gene expression datasets of diseases presented with ‘ataxia’ or ‘spasticity’ in their clinical phenotype and we performed pathway analysis in order to: (a) search for candidate perturbed pathways of SA; and (b) evaluate the role of sphingolipid signaling pathway and sphingolipid metabolism in the disease development, through the identification of differentially expressed genes in patients compared to controls. Our results demonstrate consistent differential expression of genes that participate in the sphingolipid pathways and highlight alterations in the pathway level that might be associated with the disease phenotype. Through enrichment analysis, we discuss additional pathways that are connected to sphingolipid pathways, such as PI3K-Akt signaling, MAPK signaling, calcium signaling, and lipid and carbohydrate metabolism as the most enriched for ataxia and spasticity phenotypes.

Verified
Journal Article
Open access
PDF file
AKAndrea Kakouri
Andrea Kakouri
MSMARIA SPILIOTAKI
MARIA SPILIOTAKI
Constantinos DeltasConstantinos Deltas
Constantinos Deltas
GPGregory Papagregoriou
Gregory Papagregoriou
Haris CharalambousHaris Charalambous
Haris Charalambous
Circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs) have emerged as promising non-invasive biomarkers for the immunotherapy response in advanced non-small cell lung cancer (NSCLC). However, their clinical utility remains uncertain due to variability in findings across studies. We conducted a systematic review and meta-analysis of studies from 2014 to 2024, assessing the predictive value of ctDNA and CTCs in advanced NSCLC patients receiving immunotherapy. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Forty-four studies were included (28 ctDNA, 16 CTC cohorts). High baseline ctDNA was associated with worse OS (pooled HR = 1.38, 95% CIs: 1.17–1.63), while baseline CTC detection predicted worse PFS (pooled HR of 3.65 (95% CIs: 1.58–8.41) and OS (pooled HR = 2.30, 95% CIs: 1.54–3.44). An on-treatment ctDNA decrease or clearance was associated with improved PFS (pooled HR = 0.34, 95% CIs: 0.25–0.47) and OS (pooled HR = 0.33, 95% CIs: 0.24–0.44). Evidence for other ctDNA- and CTC-derived biomarkers (blood tumour mutational burden, genomic alterations, dynamic CTC changes, and CTC PD-L1 expression) was limited or inconsistent. The interpretation of these findings is limited by heterogeneity in assay platforms, biomarker definitions, the analytical threshold, and sampling timepoints across studies. While ctDNA and CTCs show significant potential as predictive biomarkers in advanced NSCLC, further validation is needed in larger prospective studies using standardized assays. At present, ctDNA and CTC monitoring can complement but cannot replace radiological assessments in guiding immunotherapy decisions for NSCLC patients.